PSIWM
SRNE

Paradigm Strategies in Wealth Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Paradigm Strategies in Wealth Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,590
Closed -$15K – 252
2021
Q2 		$15K Hold
1,590
– – 0.01% 151
2021
Q1 		$13K Buy
+1,590
New +$16.8K 0.01% 151

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Paradigm Strategies in Wealth Management's SRNE Position: Q3 2021 in Review

Paradigm Strategies in Wealth Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2021, closing a stake of 1,590 shares — an estimated $15K sold.

Paradigm Strategies in Wealth Management first reported a position in SRNE in Q1 2021 and held it in 2 quarters. The position peaked at $15K in Q2 2021. 220 funds tracked by Wall St. Rank hold SRNE as of Q3 2021.

  • Paradigm Strategies in Wealth Management reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
  • Paradigm Strategies in Wealth Management sold 1,590 Sorrento Therapeutics, Inc. shares in Q3 2021, an estimated $15K.
  • Paradigm Strategies in Wealth Management first reported a position in Sorrento Therapeutics, Inc. in Q1 2021 and held it in 2 quarters.
  • Paradigm Strategies in Wealth Management's Sorrento Therapeutics, Inc. position peaked at $15K in Q2 2021.
  • 220 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2021.

Based on Paradigm Strategies in Wealth Management's 13F filing for Q3 2021, filed 15 Oct 2021.